|Title||PMC-309 to receive government grant from KDDF for preclinical studies _Korea Biomedical Review|
PMC-309 to receive government grant from KDDF for preclinical studies
PharmAbcine, a clinical-stage biotech company focusing on the development of next-generation antibody therapeutics, announced today that the Company will receive government grant for preclinical studies of PMC-309, one of the Company’s first immuno-oncology candidates.
PMC-309 is a first-in-class anti-VISTA antibody candidate that blocks VISTA pathways on immunosuppressive cells and promotes T cells’ immune responses and better anti-tumor effects. The molecule is currently undergoing GLP-Tox studies and expected to enter a clinical stage in 2022.
KDDF (Korea Drug Development Fund), a government drug development project that aims to strengthen the competitiveness of Korean biopharmaceutical companies, will provide PharmAbcine with research fund for up to two years.
■ Visit the link below for more information.